Quick Answer
4D Molecular Therapeutics, Inc. reported Total Assets of $566.71 million for fiscal year 2025.
4D Molecular Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $566.71M | +1.1% |
| 2024 | $560.38M | +64.9% |
| 2023 | $339.89M | +29.8% |
| 2022 | $261.85M | -25.9% |
| 2021 | $353.49M | +22.6% |
| 2020 | $288.33M | +395.1% |
| 2019 | $58.23M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $423.98M | -29.8% | -10.5% |
| June 30, 2025 | $473.64M | -23.6% | -8.2% |
| March 31, 2025 | $515.73M | -18.1% | -8.0% |
| December 31, 2024 | $560.38M | +64.9% | -7.2% |
| September 30, 2024 | $604.03M | +67.0% | -2.6% |
| June 30, 2024 | $620.12M | +75.9% | -1.6% |
| March 31, 2024 | $629.88M | +158.1% | +85.3% |
| December 31, 2023 | $339.89M | +29.8% | -6.0% |
- 4D Molecular Therapeutics, Inc. showed an increase of +1.1% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, 4D Molecular Therapeutics, Inc.’s total assets has grown by 873.2% (from $58.23 million to $566.71 million).
- The most recent figure is from 4D Molecular Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: